采用短回波时间反转恢复磁共振成像技术检测曲安奈德治疗格雷夫斯眼病
Triamcinolone for the Treatment of Graves Ophthalmopathy Tested With Short Tau Inversion Recovery Magnetic Resonance.
机构信息
Department of Ophthalmology.
Department of Diagnostic Imaging, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
出版信息
Ophthalmic Plast Reconstr Surg. 2019 Jan/Feb;35(1):22-24. doi: 10.1097/IOP.0000000000001125.
PURPOSE
To evaluate if parabulbar triamcinolone reduces orbital swelling in patients with Graves ophthalmopathy.
METHODS
This is a prospective study of a series of patients with active and moderate Graves ophthalmopathy. Short tau inversion recovery magnetic resonance was used to evaluate the intensity of the extraocular rectus muscles and orbital fat, before and after the treatment with parabulbar triamcinolone.
RESULTS
The signal intensity ratio of the sum of the OD rectus muscles was 3.67 before treatment (95% CI, 3.26-4.09) and 2.83 after treatment (95% CI, 2.63-3.03) (p < 0.001), and of the muscles of the left orbit, 3.94 before treatment (95% CI, 3.50-4.38) and 2.85 after treatment (95% CI, 2.56-3.14) (p < 0.001). The signal intensity ratio of the fat decreased from 2.95 (95% CI, 2.69-3.21) to 2.33 (95% CI, 2.07-2.58) (p < 0.001). After treatment, there were no local or systemic complications.
CONCLUSION
The use of parabulbar triamcinolone reduces orbital inflammation of patients with active and moderate Graves ophthalmopathy.
目的
评估球旁注射曲安奈德是否能减轻格雷夫斯眼病患者的眶周肿胀。
方法
这是一项前瞻性研究，纳入了一系列活动期和中度格雷夫斯眼病患者。采用短 tau 反转恢复磁共振成像（STIR MRI）评估眼外直肌和眶内脂肪的强度，在球旁注射曲安奈德前后进行。
结果
治疗前右眼外直肌总和信号强度比为 3.67（95%可信区间，3.26-4.09），治疗后为 2.83（95%可信区间，2.63-3.03）（p<0.001）；左眼外直肌总和信号强度比为 3.94（95%可信区间，3.50-4.38），治疗后为 2.85（95%可信区间，2.56-3.14）（p<0.001）。脂肪的信号强度比从 2.95（95%可信区间，2.69-3.21）降至 2.33（95%可信区间，2.07-2.58）（p<0.001）。治疗后无局部或全身并发症。
结论
球旁注射曲安奈德可减轻活动期和中度格雷夫斯眼病患者的眶内炎症。
Zotero 插件